Highlights Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
47.99 ^USD	+1.89%		-4.00%	+347.25%

May. 08	Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating	MT
May. 08	Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 10	MT
Sector Update: Health Care	Apr. 10	MT
Janux Therapeutics Said to be Considering Sale	Apr. 10	MT
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports	Apr. 10	MT
Janux Therapeutics Q4 Net Loss Narrows, Revenue Decreases	Mar. 08	MT
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 08	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Key Data for Rate-Cut Hints	Feb. 27	MT
Janux Therapeutics, Inc. Announces Positive Updated Clinical Data for Both of its Clinical Programs	Feb. 26	CI
Janux Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Janux Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1A Dose Escalation for Psma-Tractr Janx007 and an Update on Pipeline Programs	23-07-17	CI
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
JANUX THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-10	AQ
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
Janux Therapeutics' Q4 Loss Widens, Revenue Rises	23-03-10	MT
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-10	CI
Janux Therapeutics Submits Investigational New Drug Application to FDA for Drug to Treat Solid Tumors	22-12-27	MT
Janux Therapeutics, Inc. Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors	22-12-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Highlights

Filters